COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC), ACCORDING TO THE RECOMMENDED BRAZILIAN GUIDELINES FOR HTA

被引：0
|
作者：
Saggia, M. G. [1 ]
Nasciben, V. D. [2 ]
Santos, E. V. [1 ]
机构：
[1] Roche Pharmaceut, Hlth Econ, Sao Paulo, Brazil
[2] Prod Roche Quim & Farmaceut, Hlth Econ, Sao Paulo, Brazil
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [41] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF ABIRATERONE (TAROSYN® AND AVITOSYN®) AS SECOND LINE TREATMENT FOR METASTATIC PROSTATE CANCER RESISTANT TO CASTRATION IN MEXICO
    Dominguez, C.
    Sanchez, P.
    Monteon, I
    Mercado, I
    Hernandez, Ja Paladio
    VALUE IN HEALTH, 2024, 27 (12)
  • [42] Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).
    Koopman, Miriam
    Simkens, Lieke H. J.
    Ten Tije, Albert J.
    Creemers, Geert-Jan
    Loosveld, Olaf J. L.
    de Jongh, Felix E.
    Erdkamp, Frans
    Erjavec, Zoran
    van der Torren, Adelheid M. E.
    Van der Hoeven, Jacobus J. M.
    Nieboer, Peter
    Braun, J. J.
    Jansen, Rob L.
    Haasjes, Janny G.
    Cats, Annemieke
    Wals, Jacob J.
    Mol, Linda
    Dalesio, Otilia
    van Tinteren, Harm
    Punt, Cornelis J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC).
    Muñoz, A
    Salud, A
    Alonso, V
    Escudero, P
    Sanz, JJ
    Martín, C
    Rivera, F
    Yubero, A
    García-Girón, C
    López-Vivanco, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 272S - 272S
  • [44] Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): A pooled analysis of randomized phase II-III trials
    Porschen, R.
    Arkenau, H.
    Arnold, D.
    Cassidy, J.
    Diaz-Rubio, E.
    Douillard, J.
    Grothey, A.
    Hinke, A.
    Schmiegel, W.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial
    Bennouna, J.
    Faroux, R.
    Francois, E.
    Ligeza, C.
    El Hannani, C.
    Perrier, H.
    Jacob, J.
    Desseigne, F.
    Perrocheau, G.
    Douillard, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] COST-MINIMIZATION OF LORLATINIB VERSUS ALECTINIB FOR FIRST LINE TREATMENT FOR TREATMENT OF ALKPOSITIVE NON-SMALL-CELL LUNG CANCER FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Senna, T.
    Alexandre, R. F.
    Almeida, P.
    Sebastiao, M.
    Ferreira, P.
    VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
  • [47] A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC): A UK PERSPECTIVE
    Ducournau, P.
    Lewis, G.
    McDonald, A.
    Millar, D. R.
    Sabate, E.
    Walzer, S.
    VALUE IN HEALTH, 2008, 11 (06) : A472 - A473
  • [48] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
    Ducreux, Michel
    Bennouna, Jaafar
    Hebbar, Mohamed
    Ychou, Marc
    Lledo, Gerard
    Conroy, Thierry
    Adenis, Antoine
    Faroux, Roger
    Rebischung, Christine
    Bergougnoux, Loic
    Kockler, Leila
    Douillard, Jean-Yves
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) : 682 - 690
  • [49] Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
    P.-F Zhang
    F. Wen
    J. Zhou
    J.-X. Huang
    K.-X. Zhou
    Q.-J. Wu
    X.-Y. Wang
    M.-X. Zhang
    W.-T. Liao
    Q. Li
    Clinical and Translational Oncology, 2020, 22 : 103 - 110
  • [50] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345